These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 36761060)

  • 1. New Therapeutic Approaches to the Treatment of Dyslipidemia 1: ApoC-III and ANGPTL3.
    Kim JY; Kim NH
    J Lipid Atheroscler; 2023 Jan; 12(1):23-36. PubMed ID: 36761060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triglyceride-rich lipoproteins, apolipoprotein C-III, angiopoietin-like protein 3, and cardiovascular events in older adults: Atherosclerosis Risk in Communities (ARIC) study.
    Hussain A; Sun C; Selvin E; Nambi V; Coresh J; Jia X; Ballantyne CM; Hoogeveen RC
    Eur J Prev Cardiol; 2022 Mar; 29(2):e53-e64. PubMed ID: 33580780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses?
    Chan DC; Watts GF
    Curr Opin Lipidol; 2024 Jun; 35(3):101-109. PubMed ID: 38372218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease?
    Reeskamp LF; Tromp TR; Stroes ESG
    Curr Opin Lipidol; 2020 Jun; 31(3):140-146. PubMed ID: 32324598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets.
    Akoumianakis I; Zvintzou E; Kypreos K; Filippatos TD
    Curr Atheroscler Rep; 2021 Mar; 23(5):20. PubMed ID: 33694000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ANGPTL3 as a Drug Target in Hyperlipidemia and Atherosclerosis.
    Mohamed F; Mansfield BS; Raal FJ
    Curr Atheroscler Rep; 2022 Dec; 24(12):959-967. PubMed ID: 36367663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New medications targeting triglyceride-rich lipoproteins: Can inhibition of ANGPTL3 or apoC-III reduce the residual cardiovascular risk?
    Olkkonen VM; Sinisalo J; Jauhiainen M
    Atherosclerosis; 2018 May; 272():27-32. PubMed ID: 29544086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiopoietin-Like Protein 3 (ANGPTL3) Modulates Lipoprotein Metabolism and Dyslipidemia.
    Chen PY; Gao WY; Liou JW; Lin CY; Wu MJ; Yen JH
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia.
    Nurmohamed NS; Dallinga-Thie GM; Stroes ESG
    Expert Rev Cardiovasc Ther; 2020 Jun; 18(6):355-361. PubMed ID: 32511037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia.
    Ruscica M; Zimetti F; Adorni MP; Sirtori CR; Lupo MG; Ferri N
    Pharmacol Res; 2020 Mar; 153():104653. PubMed ID: 31931117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New insights into ANGPLT3 in controlling lipoprotein metabolism and risk of cardiovascular diseases.
    Su X; Peng DQ
    Lipids Health Dis; 2018 Jan; 17(1):12. PubMed ID: 29334984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Angiopoietin-Like Protein 3 or 3/8 Complex and ApoC-III in Severe Hypertriglyceridemia.
    Larouche M; Khoury E; Brisson D; Gaudet D
    Curr Atheroscler Rep; 2023 Dec; 25(12):1101-1111. PubMed ID: 38095804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD.
    Taskinen MR; Packard CJ; Borén J
    Curr Atheroscler Rep; 2019 May; 21(8):27. PubMed ID: 31111320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance.
    Ramms B; Patel S; Nora C; Pessentheiner AR; Chang MW; Green CR; Golden GJ; Secrest P; Krauss RM; Metallo CM; Benner C; Alexander VJ; Witztum JL; Tsimikas S; Esko JD; Gordts PLSM
    J Lipid Res; 2019 Aug; 60(8):1379-1395. PubMed ID: 31092690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Tale of Two New Targets for Hypertriglyceridaemia: Which Choice of Therapy?
    Ward NC; Chan DC; Watts GF
    BioDrugs; 2022 Mar; 36(2):121-135. PubMed ID: 35286660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ANGPTL3 as therapeutic target.
    Kersten S
    Curr Opin Lipidol; 2021 Dec; 32(6):335-341. PubMed ID: 34581310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drugs that Mimic the Effect of Gene Mutations for the Prevention or the Treatment of Atherosclerotic Disease: From PCSK9 Inhibition to ANGPTL3 Inactivation.
    Athyros VG; Katsiki N; Dimakopoulou A; Patoulias D; Alataki S; Doumas M
    Curr Pharm Des; 2018; 24(31):3638-3646. PubMed ID: 30306859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enrichment of Triglyceride-Rich Lipoproteins with Apolipoprotein C-I Is Positively Associated with Their Delayed Plasma Clearance Independently of Other Transferable Apolipoproteins in Postmenopausal Overweight and Obese Women.
    Wassef H; Bissonnette S; Dufour R; Davignon J; Faraj M
    J Nutr; 2017 May; 147(5):754-762. PubMed ID: 28356429
    [No Abstract]   [Full Text] [Related]  

  • 19. Exploring apolipoprotein C-III: pathophysiological and pharmacological relevance.
    Packard CJ; Pirillo A; Tsimikas S; Ference BA; Catapano AL
    Cardiovasc Res; 2024 Feb; 119(18):2843-2857. PubMed ID: 38039351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher ANGPTL3, apoC-III, and apoB48 dyslipidemia, and lower lipoprotein lipase concentrations are associated with dysfunctional visceral fat in adolescents with obesity.
    Rodríguez-Mortera R; Caccavello R; Garay-Sevilla ME; Gugliucci A
    Clin Chim Acta; 2020 Sep; 508():61-68. PubMed ID: 32407781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.